First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.…
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
First Tracks Biotherapeutics (NASDAQ: TRAX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 104 employees.
The shares were at 41.64 USD on 20 November 2026. Its 52-week range is 14.79 USD to 54.78 USD: the price is 24.0% below the high and 181.5% above the low.
Its market capitalisation is 1.75B USD.
First Tracks Biotherapeutics reports return on equity of -41.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 151.85M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 75.17 USD is 80.5% above the current price. The next earnings report is expected on 23 February 2027.